Early Identification and Intervention for Psychosis

Early identification of individuals at elevated risk for psychosis has become central to reducing the burden of schizophrenia spectrum disorders worldwide. The prodromal phase, often manifesting as subtle cognitive disturbances, mood dysregulation and attenuated psychotic symptoms, offers a critical window for preventive strategies. Comprehensive clinical assessments, structured interviews and emerging digital platforms facilitate timely detection of at-risk states, often referred to as clinical high-risk (CHR) or ultra-high-risk (UHR) syndromes. Complementing these assessments, multimodal biomarkers—from genetic profiles and electrophysiological signatures to neuroimaging measures—are being integrated into predictive algorithms that stratify risk and personalise intervention. Early intervention programmes combine psychosocial therapies, cognitive remediation and, in selected cases, pharmacological approaches to delay or prevent the transition to full-blown psychosis. Longitudinal studies suggest that such strategies can improve functional outcomes, reduce the duration of untreated psychosis and mitigate long-term disability. Global collaborations and harmonised protocols now aim to standardise screening, refine risk calculators and evaluate cost-effective outreach models, ensuring equitable access across diverse healthcare settings. Together, these advances herald a shift from reactive to proactive care in psychiatry, emphasising prevention, precision risk stratification and patient-centred support.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Early Identification and Intervention for Psychosis publication trend

The graph below shows the total number of articles in early identification and intervention for psychosis across all publications each year (not limited to Nature Index journals).

Technical terms

Clinical high risk (CHR): A syndrome characterised by subthreshold psychotic symptoms and functional decline indicating elevated risk of psychosis.

Attenuated psychotic symptoms: Mild or brief hallucinations, delusions or thought disorganisation that do not meet full diagnostic criteria for psychosis.

Biomarker: A biological measure, such as a genetic variant, neuroimaging finding or electrophysiological signature, used to detect or predict disease risk.

Risk calculator: A statistical tool that integrates clinical and biological data to estimate an individual’s probability of transition to psychosis.

Mismatch negativity (MMN): An event-related potential reflecting automatic auditory processing, often reduced in individuals at risk of psychosis.

References

1. Recent Updates on Predicting Conversion in Youth at Clinical High Risk for Psychosis. Current Psychiatry Reports (2023).
2. Predictors of transition in patients with clinical high risk for psychosis: an umbrella review. Translational Psychiatry (2023).
3. Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry (2021).
4. Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges. Molecular Psychiatry (2022).